Efficacy of Nafamostat in Covid-19 Patients (RACONA Study)
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
RACONA is a prospective trial that will test the hypothesis that nafamostat can lower lung
function deterioration and need for intensive care admission in COVID-19 patients.
Design: Adult hospitalized COVID-19 patients will be randomized in a prospective double-blind
randomized placebo-controlled study to test the clinical efficacy of nafamostat mesylate
(administered intravenously) on top of best standard of care.
Primary outcome measures: the time-to-clinical improvement, defined as the time from
randomization to an improvement of two points (from the status at randomization) on a seven
category ordinal scale or live discharge from the hospital, whichever comes first.